Get the Stockscreener App
3.11
4.75%
-0.15
Inhibikase Therapeutics Inc stock is traded at $3.11, with a volume of 112.21K.
It is down -4.75% in the last 24 hours and up +10.51% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$3.26
Open:
$3.32
24h Volume:
112.21K
Relative Volume:
0.42
Market Cap:
$226.12M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.9936
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
+32.14%
1M Performance:
+10.51%
6M Performance:
+114.16%
1Y Performance:
+39.88%
1-Day Range:
$3.1011
$3.32
1-Week Range:
$2.28
$3.32
52-Week Range:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
678-392-3419
Address
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
3.11 | 226.12M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.68 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.88 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.93 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.69 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.82 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN
Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Cut to Neutral at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (MUN:IQT0) - Nasdaq
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy -February 12, 2025 at 07:59 am EST - Marketscreener.com
Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 2.5%What's Next? - MarketBeat
Inhibikase Thera falls as risvodetinib development paused - The Pharma Letter
Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - MSN
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Stock market today: Aclarion -99.69%, CARGO Therapeutics -76.31% among biggest losers in early trading - Business Upturn
Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – Should You Sell? - Defense World
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing R - GuruFocus.com
Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock - Yahoo Finance
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Top 5 Small-cap Pharma Stocks (Updated January 2025) - Investing News Network
Inhibikase Therapeutics Completes Amendment to Certificate of IncorporationAtlanta, Georgia – Inhibikase Therapeutics, Inc. (NYSE:IKT) recently announced the successful completion of a Special Meeting of Stockholders on January 3, 2025. During this m - Defense World
Inhibikase Therapeutics expands authorized shares - Investing.com India
Inhibikase Therapeutics expands authorized shares By Investing.com - Investing.com Australia
Contrasting CRISPR Therapeutics (NASDAQ:CRSP) & Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% HigherTime to Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher – Still a Buy? - Defense World
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Inhibikase Therapeutics Hits 52-Week High, Surpassing Market Expectations with 198% Growth - mediahousepress
Inhibikase stock soars to 52-week high, hits $3.88 - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Inhibikase Therapeutics Terminates At the Market Offering Agreement - Defense World
Inhibikase Therapeutics ends agreement with sales agent By Investing.com - Investing.com Canada
Inhibikase Therapeutics ends agreement with sales agent - Investing.com
Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% – What’s Next? - Defense World
Inhibikase Therapeutics (NYSE:IKT) Shares Up 7%Here's Why - MarketBeat
Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders - TipRanks
ARMISTICE CAPITAL, LLC Expands Stake in Inhibikase Therapeutics Inc - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) Quarterly 10-Q Report - Quartzy
Inhibikase Therapeutics Reports Q3 2024 Financial Results - TipRanks
Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c) - TipRanks
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - The Bakersfield Californian
Inhibikase Secures $275M Financing Deal, Advances PAH Drug Trial Despite Q3 Loss | IKT Stock News - StockTitan
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential - Investing.com
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential By Investing.com - Investing.com Canada
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibikase Therapeutics Inc Stock (IKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
0.03%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):